🇺🇸 FDA
Patent

US 7579333

Therapy using a combination of raloxifene and alendronate

granted A61KA61K31/445A61K31/4535

Quick answer

US patent 7579333 (Therapy using a combination of raloxifene and alendronate) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Aug 20 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Aug 25 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 20 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/445, A61K31/4535, A61K31/66, A61K31/663